0000000000023618

AUTHOR

Michel Toubeau

showing 4 related works from this author

Place de l’imagerie dans l’évaluation de l’efficacité des traitements dans le cancer du sein

2010

Resume Cette revue decrit le role de differentes methodes d’imagerie pour evaluer la reponse au traitement dans le cancer du sein. Deux situations sont envisageables : celle de la chimiotherapie neoadjuvante du cancer du sein et celle des metastases. Beaucoup de donnees cliniques sont disponibles pour trois criteres : le volume de la tumeur, la captation du fluorodeoxyglucose mesuree en TEP et la perfusion de la tumeur evaluee soit par IRM dynamique, soit en TEP. La TEP au 2-18F fluoro-2-desoxy-D-glucose (FDG) permet la prediction de la reponse apres une ou deux cures de chimiotherapie. De nouvelles approches pourraient prochainement affiner le role de l’imagerie. Ainsi, la TEP a la thymidi…

GynecologyLight nucleusmedicine.medical_specialtyOptical imagingRadiological and Ultrasound TechnologyNeoadjuvant treatmentPhilosophyBiophysicsmedicineRadiology Nuclear Medicine and imagingHuman Epidermal Growth Factor Receptor 2Médecine Nucléaire
researchProduct

18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer

2016

International audience; Previous studies have suggested that early changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with 150-water are a surrogate biomarker of outcome in women with breast cancer. This study investigates, in the triple-negative breast cancer subtype, the prognostic relevance of tumor BF changes (Delta BF) in response to chemotherapy, assessed using a short dynamic F-18-FDG PET acquisition. Methods: Forty-six consecutive women with triple-negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included. Women benefited from a baseline F-18-FDG PET examination with a 2-min chest-centered dynamic acquisition, sta…

Oncologymedicine.medical_specialtyPrognostic-FactorsBevacizumabSurvival[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineperfusion[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineblood flowRadiology Nuclear Medicine and imaging[ SDV.IB ] Life Sciences [q-bio]/BioengineeringTomography[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingNeoadjuvant therapyTriple-negative breast cancerSubtypesMarkersChemotherapytriple-negativemedicine.diagnostic_testbusiness.industryTriple Negative Breast Neoplasmsmedicine.disease3. Good healthBevacizumabPETMetabolismPositron emission tomography030220 oncology & carcinogenesisBiomarker (medicine)Pathological Response[SDV.IB]Life Sciences [q-bio]/BioengineeringAngiogenesisTherapybusinessmedicine.drug
researchProduct

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

2007

To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships betwe…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPathological responseAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSensitivity and Specificity030218 nuclear medicine & medical imaging18f fdg pet[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansRadiology Nuclear Medicine and imagingNeoadjuvant therapyComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryFdg uptakeReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseasePrognosisNeoadjuvant Therapy3. Good healthClinical trialTreatment OutcomePositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyFemaleRadiopharmaceuticalsbusiness
researchProduct

Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors

2012

The purpose of this study was to prospectively evaluate the relationship between tumor blood flow and glucose metabolism as evaluated by dynamic first-pass (18)F-FDG PET and by proliferation and endothelial pathologic markers in the setting of newly diagnosed breast cancer.Forty patients were prospectively included. Biopsy samples of each tumor were used to assess the Ki67 index of proliferation and immunostaining for CD34 (a panendothelial cell marker) and CD105 (a proliferation-related endothelial cell marker). All patients underwent (18)F-FDG PET/CT at least 1 wk after sample biopsy and before any treatment. A dynamic 2-min acquisition was performed immediately after intravenous injectio…

AdultPathologymedicine.medical_specialtyAngiogenesisStandardized uptake valueBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicineNeovascularization03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18BiopsymedicineBiomarkers Tumor[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingProspective StudiesComputingMilieux_MISCELLANEOUSAgedCell Proliferationmedicine.diagnostic_testNeovascularization Pathologicbusiness.industryEndothelial CellsBlood flowEndoglinMiddle Agedmedicine.diseasePrognosisLogistic ModelsPositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyBlood CirculationFemalemedicine.symptombusinessTomography X-Ray Computed
researchProduct